Over the past several years, it has become increasingly apparent that prevention of the functional disability associated with schizophrenia is as important as the treatment of overt psychosis. In many patients with schizophrenia, disability in every day functioning is often profound and treatment resistant, limiting recovery regardless of how well psychosis is controlled with medication. Research in adults with chronic schizophrenia has indicated that neuropsychological dysfunction and negative symptoms are more directly related to functional outcome than are positive symptoms, and that function can be separated into capacity and real-world achievement (Green et al. 1996, 2000, 2004;Harvey et al. 2009). In the proposed method advancement project, we aim to develop a multi-dimensional functional battery specifically suited to young (adolescent to young adult) individuals in the prodromal or very early stages of psychosis. The battery will consist of five measures, two global interviews measuring social and role achievement and three self-report or computerized assessments measuring social/role capacity and emerging disability. The five measures are in various stages of development, with the two global interviews most extensively validated thus far (Auther et al. 2006;Cornblatt et al. 2007a;Cannon et al. 2008;see also Clinical Assessment Strategies Unit). The overall goals of the current project are to validate these measures in three ways, by assessing: 1) the extent to which these measures reflect """"""""real world"""""""" functioning;2) whether these are sensitive to illness status;3) relationship to cognition. Following cross-sectional data collection as part of this project, an R01 is planned to prospectively investigate developmental trajectories in longitudinal data.
Specific aims for this project include: 1. To establish the psychometric properties of all five measures in the proposed test battery, including: a. Inter-rater reliability; b. Inter-relationships among the five tests to determine convergent validity and the extent to which a valid distinction can be made between functional achievement vs. capacity; c. Construct validity, i.e., the extent to which the measures reflect real world functioning based on information provided by parents, teachers and report cards; d. Age and gender norms for all measures. 2. To assess the sensitivity of the functional battery, i.e. the extent to which these measures systematically distinguish prodromal subjects from healthy controls. Once pre-illness deficits have been reliably demonstrated, the resulting final battery can be introduced into larger, future studies determining developmental course and predictive value of these assessments. 3. To evaluate the relationship between functional deficits and neurocognitive abnormality, as measured by the MATRICS battery (cf. Clinical Assessment Strategies Unit and Biomarkers Unit).

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH090590-04
Application #
8463881
Study Section
Special Emphasis Panel (ZMH1-ERB-N)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
4
Fiscal Year
2013
Total Cost
$84,371
Indirect Cost
$33,545
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Nagendra, Arundati; Schooler, Nina R; Kane, John M et al. (2018) Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. Schizophr Res 193:64-68
Karlsgodt, Katherine H; Bato, Angelica A; Ikuta, Toshikazu et al. (2018) Functional Activation During a Cognitive Control Task in Healthy Youth Specific to Externalizing or Internalizing Behaviors. Biol Psychiatry Cogn Neurosci Neuroimaging 3:133-140
Browne, Julia; Estroff, Sue E; Ludwig, Kelsey et al. (2018) Character strengths of individuals with first episode psychosis in Individual Resiliency Training. Schizophr Res 195:448-454
Robinson, Delbert G; Schooler, Nina R; Correll, Christoph U et al. (2018) Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. Am J Psychiatry 175:169-179
Baumel, Amit; Baker, Justin; Birnbaum, Michael L et al. (2018) Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. Psychiatr Serv 69:590-592
John, Majnu; Lencz, Todd; Malhotra, Anil K et al. (2018) A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene 16:143-164
Kishimoto, Taishiro; Hagi, Katsuhiko; Nitta, Masahiro et al. (2018) Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr Bull 44:603-619
DeRosse, Pamela; Nitzburg, George C; Blair, Melanie et al. (2018) Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res 195:385-390
Lyall, A E; Pasternak, O; Robinson, D G et al. (2018) Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning. Mol Psychiatry 23:701-707
Shafritz, Keith M; Ikuta, Toshikazu; Greene, Allison et al. (2018) Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging Behav :

Showing the most recent 10 out of 120 publications